Reprogrammed metabolism has been long recognized as a driver of kidney cancer progression, prompting efforts to develop metabolic targeted therapies against this disease. Evidence offers further clarity on the metabolic phenotypes associated with aggressive disease, expanding the potential target space for attacking these tumours at their metabolic roots.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tran, J. & Ornstein, M. C. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol. Pract. 18, 187–196 (2022).
Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277–285 (2010).
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).
Hu, J. et al. Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression. Nat. Genet. 56, 442–457 (2024).
Ericsson, J. L., Seljelid, R. & Orrenius, S. Comparative light and electron microscopic observations of the cytoplasmic matrix in renal carcinomas. Virchows Arch. Pathol. Anat. Physiol. Klin. Med. 341, 204–223 (1966).
Li, Y. et al. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell 41, 139–163.e17 (2023).
Hakimi, A. A. et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29, 104–116 (2016).
Ricketts, C. J. et al. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 313–326.e5 (2018).
Stine, Z. E., Schug, Z. T., Salvino, J. M. & Dang, C. V. Targeting cancer metabolism in the era of precision oncology. Nat. Rev. Drug Discov. 21, 141–162 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Lawson, K.A., Linehan, W.M. De-clear cell differentiated renal cell carcinoma — a new therapeutic target. Nat Rev Urol (2024). https://doi.org/10.1038/s41585-024-00911-w
Published:
DOI: https://doi.org/10.1038/s41585-024-00911-w
